Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.

Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.

Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Abstract: The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.

Abstract: A conjugate of formula (I) wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain.

Abstract: A conjugate of formula I: L-(DL)p??(I) wherein L is a Ligand unit, DL is a Drug Linker unit of formula II: wherein either: (a) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) R11 is OH, and R10 is: p is an integer of from 1 to 20.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): where Y is H or F, with a single overall linker moiety connecting two topoisomerase inhibitor derivatives to a Ligand Unit, wherein the topoisomerase inhibitor derivatives are cleavable from the Ligand Unit. Also provided is A* with the linking unit attached, and intermediates for their synthesis.

Abstract: A compound with the formula I: (I) and salts and solvates thereof, wherein: R? is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.

Abstract: A conjugate of formula I: L-(DL)P??(1) wherein L is a Ligand unit, DL is a Drug Linker unit of formula II: wherein either: (a) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (b) R11 is OH, and R10 is: p is an integer of from 1 to 20.

Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NRN2 (where RN2 is H or C1-4 alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y? are selected from O, S, or NH; R6, R7, R9 are selected from the same groups as R6, R7 and R9 respectively; R11b is selected from OH, ORA, where RA is C1-4 alkyl; and RL is a linker for connection to a cell binding agent.

Abstract: A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.

Abstract: A method of synthesising a compound of formula (I) from a compound of formula (II) wherein R2 is phenyl, substituted at either the meta- or para-position by the group (III) where Q is an amino acid residue (—C(?O)—X1—NH—), a di-amino acid residue (—C(?O)—X1—X2—NH—) or a tri-amino acid residue (—C(?O)—X1—X2—X3—NH—); ProtN3 is an amino protecting group; R2pre is phenyl, substituted at the same position as R2 by —NH2; comprising reacting a compound of formula (II) with a compound of formula (IV) in the presence of HATU in dichloromethane or chloroform or a mixture thereof.

Abstract: A compound of formula (I) and salts and solvates thereof, wherein RL is a linker for connection to a cell binding agent, which is formula (IIa) wherein Q is a tripeptide residue of formula (A), where x is 1 or 2, —C(?O)-Qx-NH— is a dipeptide residue; X is: formula (B), where a=0 to 5, b=0 to 16, c=0 or 1, d=0 to 5; and GL is a linker for connecting to a Ligand Unit.